NVS - Novartis AG

NYSE - Nasdaq Real Time Price. Currency in USD
87.65
+0.41 (+0.47%)
As of 10:38AM EST. Market open.
Stock chart is not supported by your current browser
Previous Close87.24
Open86.88
Bid87.52 x 1200
Ask87.55 x 1300
Day's Range86.86 - 87.71
52 Week Range72.30 - 94.19
Volume556,369
Avg. Volume2,268,684
Market Cap202.464B
Beta (3Y Monthly)0.85
PE Ratio (TTM)15.36
EPS (TTM)5.71
Earnings DateN/A
Forward Dividend & Yield2.98 (3.34%)
Ex-Dividend Date2018-03-06
1y Target Est98.50
Trade prices are not sourced from all markets
  • Reuters23 hours ago

    Novartis launches third-to-market Remicade copy in Germany

    Novartis launched a copy of Johnson & Johnson's (J&J) inflammation-fighting Remicade in Germany on Thursday as the Swiss drugmaker aims to catch rival biosimilars that are already available in Europe's largest healthcare market. Novartis's Sandoz generics unit in May won European approval for Zessly, known generically as infliximab.

  • The Zacks Analyst Blog Highlights: Chevron, Novartis, Qualcomm, TJX and Deere
    Zacksyesterday

    The Zacks Analyst Blog Highlights: Chevron, Novartis, Qualcomm, TJX and Deere

    The Zacks Analyst Blog Highlights: Chevron, Novartis, Qualcomm, TJX and Deere

  • Reutersyesterday

    Novartis 'completely committed' to Sandoz, has no split-off plan

    Swiss drugmaker Novartis (NOVN.S) is "completely committed" to its $10 billion-per-year Sandoz generics business, a spokesman said on Thursday, after a newspaper reported Chief Executive Vas Narasimhan planned to split the unit off. "We're completely committed to the Sandoz business, and we're looking at transforming it and making it as strong as it can be in the global generics business," Novartis spokesman Sreejit Mohan told Reuters. Earlier, Swiss newspaper Tages-Anzeiger reported the Basel-based drugmaker was preparing to split off Sandoz, citing an employee representative as well as participants in a Novartis investor event last week in London.

  • Reutersyesterday

    Novartis 'completely committed' to Sandoz, has no split-off plan

    Swiss drugmaker Novartis is "completely committed" to its $10 billion-per-year Sandoz generics business, a spokesman said on Thursday, after a newspaper reported Chief Executive Vas Narasimhan planned to split the unit off. "We're completely committed to the Sandoz business, and we're looking at transforming it and making it as strong as it can be in the global generics business," Novartis spokesman Sreejit Mohan told Reuters.

  • Reutersyesterday

    Novartis says 'completely committed' to Sandoz, not planning split-off

    Swiss drugmaker Novartis is "completely committed" to its $10 billion-per-year Sandoz generics business, a spokesman said on Thursday, after a newspaper reported Chief Executive Vas Narasimhan ...

  • Migraine-Focused Biotech Has A Headache On Quarterly Losses
    Investor's Business Daily2 days ago

    Migraine-Focused Biotech Has A Headache On Quarterly Losses

    Biohaven Pharmaceutical slumped to a three-week low Wednesday after the biotech reported greater-than-expected third-quarter losses.

  • Novartis AG (NVS) Not Doing Enough to Attract Smart Money
    Insider Monkey2 days ago

    Novartis AG (NVS) Not Doing Enough to Attract Smart Money

    Concerns over rising interest rates and expected further rate increases have hit several stocks hard since the end of the third quarter. The NASDAQ and Russell 2000 indices are already in correction territory. More importantly, the Russell 2000 ETF (IWM) underperformed the larger S&P 500 ETF (SPY) by about 4 percentage points in October. Hedge […]

  • Jazz Pharmaceuticals: How Are Xyrem and Erwinaze Positioned?
    Market Realist3 days ago

    Jazz Pharmaceuticals: How Are Xyrem and Erwinaze Positioned?

    Jazz Pharmaceuticals’ (JAZZ) Xyrem generated revenues of $357.3 million in the third quarter—compared to $303.9 million in the third quarter of 2017, which reflected ~18% YoY (year-over-year) growth. Xyrem’s net revenues over the first nine months of 2018 amounted to $1.0 billion—compared to $874.2 million in the same period in 2017, which reflects 18% YoY growth.

  • Tilray (TLRY) to Report Q3 Earnings: What's in the Cards?
    Zacks4 days ago

    Tilray (TLRY) to Report Q3 Earnings: What's in the Cards?

    We expect investors to focus on Tilray's (TLRY) pipeline updates when it reports third-quarter results.

  • These Biopharmas Could Cure Genetic Diseases — At $5 Million Apiece
    Investor's Business Daily4 days ago

    These Biopharmas Could Cure Genetic Diseases — At $5 Million Apiece

    Novartis and Audentes could hold the keys to curing a pair of genetic diseases — but they will cost $4 million to $5 million apiece, an analyst predicted Monday.

  • Ligand (LGND) Beats on Q3 Earnings & Revenues, Raises View
    Zacks7 days ago

    Ligand (LGND) Beats on Q3 Earnings & Revenues, Raises View

    Ligand (LGND) beats earnings and sales estimates in the third quarter of 2018 and raises full-year guidance for the second straight quarter.

  • Reuters8 days ago

    Novartis division Sandoz recalls one lot of blood pressure drug

    Novartis said on Thursday its Sandoz division was recalling one lot of losartan tablets after finding traces of a probable carcinogen in the blood pressure drug. The drug is made by China's Zhejiang Huahai Pharmaceutical Co Ltd. Last month, the European Medicines Agency placed the firm under high supervision after a probable carcinogen was found in its blood pressure drug valsartan. A review was extended to other 'sartan' medicines, including candesartan, irbesartan, losartan, olmesartan and valsartan, after very low levels of a carcinogen was found in losartan made by Hetero Labs in India.

  • Ligand Pharmaceuticals Inc (LGND) Q3 2018 Earnings Conference Call Transcript
    Motley Fool8 days ago

    Ligand Pharmaceuticals Inc (LGND) Q3 2018 Earnings Conference Call Transcript

    LGND earnings call for the period ending September 30, 2018.

  • Mylan’s Major Drivers: Biosimilars and Asset Acquisitions
    Market Realist8 days ago

    Mylan’s Major Drivers: Biosimilars and Asset Acquisitions

    On June 4, the FDA issued a press release announcing regulatory approval for a biosimilar version of Amgen’s (AMGN) Neulasta and Mylan’s (MYL) Fulphilia. On September 20, the European Medicines Agency issued a press release announcing a positive opinion from the Committee for Medicinal Products for Human Use for Fulphila. According to Mylan’s investor presentation, Fulphila is targeting a global market opportunity worth more than $5.0 billion.

  • Here's Why PTC Therapeutics Dropped 18% in October
    Motley Fool9 days ago

    Here's Why PTC Therapeutics Dropped 18% in October

    The company's development-stage SMA treatment was supposed to knock out the market leader, but now it may be the one at risk of an upset.

  • This Rockville biotech is expanding to a new HQ. Here are the details.
    American City Business Journals9 days ago

    This Rockville biotech is expanding to a new HQ. Here are the details.

    The fast-growing company is consolidating into a larger headquarters in Rockville — not far from its current home.

  • Amgen (AMGN) Counts on New Drugs Amid Rising Biosimilar Woes
    Zacks9 days ago

    Amgen (AMGN) Counts on New Drugs Amid Rising Biosimilar Woes

    Amgen's newer drugs, Prolia, Xgeva, Kyprolis, are driving sales. Lower sales of mature drugs like Enbrel and biosimilar competition for Neulasta/Epogen are concerns.

  • Ionis Pharmaceuticals, Inc. (IONS) Q3 2018 Earnings Conference Call Transcript
    Motley Fool10 days ago

    Ionis Pharmaceuticals, Inc. (IONS) Q3 2018 Earnings Conference Call Transcript

    IONS earnings call for the period ending September 30, 2018.

  • What Lies in Store for Ligand (LGND) This Earnings Season?
    Zacks10 days ago

    What Lies in Store for Ligand (LGND) This Earnings Season?

    Ligand's (LGND) partnered programs - Kyprolis and Promacta - using its Captisol formulation technology are expected to drive milestone and royalty payments in third-quarter 2018.

  • 4 months after drug approval, Achaogen eyes fire sale
    American City Business Journals11 days ago

    4 months after drug approval, Achaogen eyes fire sale

    The company, which had hired close to 90 people leading up to its first drug approval, has been cutting jobs since the FDA said its antibiotic could be used in one type of infection but not another.

  • Reuters14 days ago

    Novartis abandons effort for U.S. approval of biosimilar rituximab

    Novartis International AG said on Friday that its Sandoz division is abandoning an effort to gain U.S. regulatory approval for a biosimilar of rituximab, a medication used to treat certain cancer and rheumatoid arthritis. The decision comes after the U.S. Food and Drug Administration (FDA) sought additional information to support the company's application for the drug, which is approved already in the EU, Switzerland, Japan and Australia, the company said in a statement. "We are disappointed to have to make this decision and stand behind the safety, efficacy and quality of our medicine," said Stefan Hendriks, global head of biopharmaceuticals at Sandoz.

  • PR Newswire14 days ago

    Novartis data at ASH and SABCS show strength of pipeline and portfolio in hematology and oncology

    - Additional analysis from pivotal Phase III SOLAR-1 clinical trial studying investigational alpha-specific PI3K inhibitor BYL719 (alpelisib) and fulvestrant in patients with PIK3CA-mutated HR+/HER2- advanced ...

  • Conatus' (CNAT) Q3 Loss In Line, Revenues Lag Estimates
    Zacks14 days ago

    Conatus' (CNAT) Q3 Loss In Line, Revenues Lag Estimates

    Conatus (CNAT) incurs in-line loss for the third quarter of 2018. Sales miss estimates.

  • A Look at Merck’s Diabetes and Women’s Health Business
    Market Realist14 days ago

    A Look at Merck’s Diabetes and Women’s Health Business

    Merck & Co.’s (MRK) Januvia generated revenues of $927 million in the third quarter, reflecting an ~8% YoY (year-over-year) decline. In the US and international markets, Januvia generated revenues of $498 million and $429 million, respectively, reflecting a ~17% YoY decline and a ~45 YoY growth.

  • Gene therapy: CHOP unveils $75M manufacturing facility (Photos)
    American City Business Journals15 days ago

    Gene therapy: CHOP unveils $75M manufacturing facility (Photos)

    Children's Hospital of Philadelphia expects to double its viral vector manufacturing facility, to support cell and gene therapy, in its new space.